At the heart of Cocrystal's operations is its proprietary structure-based drug design platform, which allows the company to efficiently develop small-molecule antiviral therapeutics that are safe, effective, and convenient to administer. The company has garnered strategic investments from prominent industry players, including Teva Pharmaceuticals, OPKO Health, and the Frost Group.
Cyborg Score Rationale
The company has zero trailing twelve-month revenue and negative net income of approximately $4.9 million. As a clinical-stage biotech in early development, Cocrystal faces significant execution and funding risks typical of pre-commercial antiviral drug developers. Recent progress on CDI-988 and partnerships provide some upside potential.
Top Insights
CDI-988, an oral pan-viral compound in Phase 1 clinical trial, targets noroviruses and coronaviruses including SARS-CoV-2 and variants
CDI-988 received FDA IND clearance with Phase 1b norovirus challenge study expected in Q1 2026
Company has research collaboration with Merck Sharp & Dohme Corp. and licensing agreement with Kansas State University for antiviral development
CC-42344, a PB2 influenza inhibitor, is in Phase 2a clinical trial and showed activity against 2024 H5N1 avian influenza
Named Competitors
Broad-spectrum antivirals — Influenza research partnership
Antiviral therapeutics — Established antiviral drug developer
Antiviral candidates — Infectious disease focus
Recent Developments
(December 2025) FDA IND clearance for CDI-988 norovirus preventive and treatment evaluation
(July 2025) CDI-988 selected for oral presentation at ICAR 2026 conference
(May 2025) CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants
Open the full interactive Cocrystal Pharma, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.